D. Boral Capital Reiterates “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $18.00 target price on the stock. D. Boral Capital’s price target points to a potential upside of 165.10% from the company’s previous close.

Separately, Chardan Capital reissued a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, February 6th.

Coya Therapeutics Stock Down 0.9 %

Shares of COYA opened at $6.79 on Tuesday. The firm has a fifty day simple moving average of $6.29 and a two-hundred day simple moving average of $6.48. Coya Therapeutics has a twelve month low of $4.75 and a twelve month high of $10.69. The stock has a market capitalization of $113.44 million, a P/E ratio of -10.45 and a beta of 0.31.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its position in shares of Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after buying an additional 4,777 shares during the period. XTX Topco Ltd bought a new position in shares of Coya Therapeutics in the 4th quarter worth approximately $59,000. Jane Street Group LLC purchased a new position in shares of Coya Therapeutics in the 4th quarter valued at approximately $74,000. Northern Trust Corp boosted its position in shares of Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after purchasing an additional 3,099 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Coya Therapeutics in the fourth quarter worth $401,000. 39.75% of the stock is currently owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.